Endometriosis - Pipeline Review - H1 2014





Published: March 2014 | Pages: 131 | Format: PDF

 Summary 

 Global Markets Direct’s, ‘Endometriosis - Pipeline Review, H1 2014’, provides an overview of the Endometriosis’s therapeutic pipeline. 

 This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued projects. 

 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. 

 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

  •  The report provides a snapshot of the global therapeutic landscape of Endometriosis 
  •  The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities  
  •  The report reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects 
  •  The report summarizes all the dormant and discontinued pipeline projects  
  •  A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
  •  Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
  •  A detailed assessment of monotherapy and combination therapy pipeline projects 
  •  Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type 
  •  Latest news and deals relating related to pipeline products 

 Reasons to buy 

  •  Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies  
  •  Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage  
  •  Develop strategic initiatives by understanding the focus areas of leading companies  
  •  Identify and understand important and diverse types of therapeutics under development for Endometriosis  
  •  Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline  
  •  Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics  
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

 

 Table of Contents 

 Introduction 10 

 Global Markets Direct Report Coverage 10 

 Endometriosis Overview 11 

 Therapeutics Development 12 

 Pipeline Products for Endometriosis - Overview 12 

 Pipeline Products for Endometriosis - Comparative Analysis 13 

 Endometriosis - Therapeutics under Development by Companies 14 

 Endometriosis - Therapeutics under Investigation by Universities/Institutes 17 

 Endometriosis - Pipeline Products Glance 19 

 Late Stage Products 19 

 Clinical Stage Products 20 

 Early Stage Products 21 

 Unknown Stage Products 22 

 Endometriosis - Products under Development by Companies 23 

 Endometriosis - Products under Investigation by Universities/Institutes 25 

 Endometriosis - Companies Involved in Therapeutics Development 26 

 Euroscreen S.A. 26 

 Takeda Pharmaceutical Company Limited 27 

 Neurocrine Biosciences, Inc. 28 

 Astellas Pharma Inc. 29 

 Kissei Pharmaceutical Co., Ltd. 30 

 SK Chemicals Co., Ltd. 31 

 Bayer AG 32 

 Addex Therapeutics 33 

 Evotec AG 34 

 ValiRx Plc 35 

 Repros Therapeutics Inc. 36 

 Dongkook Pharmaceutical Co., Ltd. 37 

 Camurus AB 38 

 Lipicard Technologies Limited 39 

 Orphagen Pharmaceuticals, Inc. 40 

 Peptron, Inc. 41 

 PregLem SA 42 

 EndoCeutics, Inc. 43 

 Isifer AB 44 

 ElexoPharm GmbH 45 

 APAvadis Biotechnologies Srl 46 

 AbbVie Inc. 47 

 Balonco GMBH 48 

 Forendo Pharma Oy 49 

 Endometriosis - Therapeutics Assessment 50 

 Assessment by Monotherapy Products 50 

 Assessment by Combination Products 51 

 Assessment by Target 52 

 Assessment by Mechanism of Action 55 

 Assessment by Route of Administration 58 

 Assessment by Molecule Type 60 

 Drug Profiles 62 

 elagolix sodium - Drug Profile 62 

 Product Description 62 

 Mechanism of Action 62 

 R&D Progress 62 

 leuprolide acetate SR - Drug Profile 64 

 Product Description 64 

 Mechanism of Action 64 

 R&D Progress 64 

 degarelix - Drug Profile 65 

 Product Description 65 

 Mechanism of Action 65 

 R&D Progress 65 

 (acolbifene + DHEA + GnRH agonist) - Drug Profile 66 

 Product Description 66 

 Mechanism of Action 66 

 R&D Progress 66 

 relugolix - Drug Profile 67 

 Product Description 67 

 Mechanism of Action 67 

 R&D Progress 67 

 telapristone acetate - Drug Profile 68 

 Product Description 68 

 Mechanism of Action 68 

 R&D Progress 68 

 PGL-2001 - Drug Profile 70 

 Product Description 70 

 Mechanism of Action 70 

 R&D Progress 70 

 KLH-2109 - Drug Profile 72 

 Product Description 72 

 Mechanism of Action 72 

 R&D Progress 72 

 ASP-1707 - Drug Profile 73 

 Product Description 73 

 Mechanism of Action 73 

 R&D Progress 73 

 Endole - Drug Profile 74 

 Product Description 74 

 Mechanism of Action 74 

 R&D Progress 74 

 bentamapimod - Drug Profile 75 

 Product Description 75 

 Mechanism of Action 75 

 R&D Progress 75 

 teverelix - Drug Profile 76 

 Product Description 76 

 Mechanism of Action 76 

 R&D Progress 76 

 BAY-1026153 - Drug Profile 78 

 Product Description 78 

 Mechanism of Action 78 

 R&D Progress 78 

 ADX-68692 - Drug Profile 79 

 Product Description 79 

 Mechanism of Action 79 

 R&D Progress 79 

 ESN-364 - Drug Profile 80 

 Product Description 80 

 Mechanism of Action 80 

 R&D Progress 80 

 VAL-201 - Drug Profile 81 

 Product Description 81 

 Mechanism of Action 81 

 R&D Progress 81 

 leuprolide acetate - Drug Profile 82 

 Product Description 82 

 Mechanism of Action 82 

 R&D Progress 82 

 GnRH Antagonists - Drug Profile 83 

 Product Description 83 

 Mechanism of Action 83 

 R&D Progress 83 

 Small Molecule to Inhibit 17 Beta-HSD1 for Endometriosis and Breast Cancer - Drug Profile 84 

 Product Description 84 

 Mechanism of Action 84 

 R&D Progress 84 

 HSD Research Program - Drug Profile 85 

 Product Description 85 

 Mechanism of Action 85 

 R&D Progress 85 

 Small Molecules For Endometriosis - Drug Profile 86 

 Product Description 86 

 Mechanism of Action 86 

 R&D Progress 86 

 NCE-403 - Drug Profile 87 

 Product Description 87 

 Mechanism of Action 87 

 R&D Progress 87 

 Aminopeptidase A Program - Drug Profile 88 

 Product Description 88 

 Mechanism of Action 88 

 R&D Progress 88 

 META Program - Drug Profile 89 

 Product Description 89 

 Mechanism of Action 89 

 R&D Progress 89 

 Drugs to Inhibit GnRH Receptor for Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology and Women Health - Drug Profile 90 

 Product Description 90 

 Mechanism of Action 90 

 R&D Progress 90 

 EVE-104 - Drug Profile 91 

 Product Description 91 

 Mechanism of Action 91 

 R&D Progress 91 

 EC-304 - Drug Profile 92 

 Product Description 92 

 Mechanism of Action 92 

 R&D Progress 92 

 triptorelin pamoate biosimilar - Drug Profile 93 

 Product Description 93 

 Mechanism of Action 93 

 R&D Progress 93 

 goserelin biosimilar - Drug Profile 94 

 Product Description 94 

 Mechanism of Action 94 

 R&D Progress 94 

 LT-6121 - Drug Profile 95 

 Product Description 95 

 Mechanism of Action 95 

 R&D Progress 95 

 Kisspeptin Peptide Antagonists - Drug Profile 96 

 Product Description 96 

 Mechanism of Action 96 

 R&D Progress 96 

 Small Molecule To Inhibit 17HSD1 For Endometriosis - Drug Profile 97 

 Product Description 97 

 Mechanism of Action 97 

 R&D Progress 97 

 Recombinant Pigment Epithelium Derived Factor - Drug Profile 98 

 Product Description 98 

 Mechanism of Action 98 

 R&D Progress 98 

 VPE-001 - Drug Profile 99 

 Product Description 99 

 Mechanism of Action 99 

 R&D Progress 99 

 Small Molecule to Inhibit 17Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 100 

 Product Description 100 

 Mechanism of Action 100 

 R&D Progress 100 

 Drug Targeting RERG for Endometriosis - Drug Profile 102 

 Product Description 102 

 Mechanism of Action 102 

 R&D Progress 102 

 Small Molecules to Inhibit Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 103 

 Product Description 103 

 Mechanism of Action 103 

 R&D Progress 103 

 Steroidogenic Factor-1 Antagonists - Drug Profile 104 

 Product Description 104 

 Mechanism of Action 104 

 R&D Progress 104 

 Program For Women Health - Drug Profile 105 

 Product Description 105 

 Mechanism of Action 105 

 R&D Progress 105 

 EMMPRIN-Conjugates - Drug Profile 106 

 Product Description 106 

 Mechanism of Action 106 

 R&D Progress 106 

 Drugs Inhibiting Axl/Gas6 Signaling - Drug Profile 107 

 Product Description 107 

 Mechanism of Action 107 

 R&D Progress 107 

 Drug to Inhibit C-Jun for Endometriosis - Drug Profile 108 

 Product Description 108 

 Mechanism of Action 108 

 R&D Progress 108 

 Endometriosis - Recent Pipeline Updates 109 

 Endometriosis - Dormant Projects 122 

 Endometriosis - Discontinued Products 123 

 Endometriosis - Product Development Milestones 124 

 Featured News & Press Releases 124 

 Oct 03, 2013: ValiRx Files Phase IB/dose escalation study for VAL201 124 

 Aug 29, 2013: Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis 124 

 Apr 25, 2013: ValiRx Receives Australian Patent For VAL201 125 

 Nov 13, 2012: Repros Presents Proellex Clinical Updates At Lazard Capital Markets 9th Annual Healthcare Conference 125 

 Oct 08, 2012: Repros Therapeutics's Proellex Receives FDA Acceptance For Reclassification Of Clinical Hold Status 126 

 Aug 27, 2012: FDA Provides Recommendations For Phase II Protocol For Repros' Proellex In Treatment Of Endometriosis 127 

 Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 127 

 Jul 16, 2012: FDA Provides Guidance To Repros For Conducting Phase II Study Of Proellex In Treatment Of Endometriosis 128 

 Jun 05, 2012: Abbott Initiates Phase III Study Of Elagolix In Patients With Endometriosis 128 

 May 29, 2012: Repros Provides Updates On Proellex Clinical Programs Status 128 

 Appendix 130 

 Methodology 130 

 Coverage 130 

 Secondary Research 130 

 Primary Research 130 

 Expert Panel Validation 130 

 Contact Us 131 

 Disclaimer 131 

  

 List of Tables 

 Number of Products under Development for Endometriosis, H1 2014 12 

 Number of Products under Development for Endometriosis - Comparative Analysis, H1 2014 13 

 Number of Products under Development by Companies, H1 2014 15 

 Number of Products under Development by Companies, H1 2014 (Contd..1) 16 

 Number of Products under Investigation by Universities/Institutes, H1 2014 18 

 Comparative Analysis by Late Stage Development, H1 2014 19 

 Comparative Analysis by Clinical Stage Development, H1 2014 20 

 Comparative Analysis by Early Stage Development, H1 2014 21 

 Comparative Analysis by Unknown Stage Development, H1 2014 22 

 Products under Development by Companies, H1 2014 23 

 Products under Development by Companies, H1 2014 (Contd..1) 24 

 Products under Investigation by Universities/Institutes, H1 2014 25 

 Endometriosis - Pipeline by Euroscreen S.A., H1 2014 26 

 Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 27 

 Endometriosis - Pipeline by Neurocrine Biosciences, Inc., H1 2014 28 

 Endometriosis - Pipeline by Astellas Pharma Inc., H1 2014 29 

 Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2014 30 

 Endometriosis - Pipeline by SK Chemicals Co., Ltd., H1 2014 31 

 Endometriosis - Pipeline by Bayer AG, H1 2014 32 

 Endometriosis - Pipeline by Addex Therapeutics, H1 2014 33 

 Endometriosis - Pipeline by Evotec AG, H1 2014 34 

 Endometriosis - Pipeline by ValiRx Plc, H1 2014 35 

 Endometriosis - Pipeline by Repros Therapeutics Inc., H1 2014 36 

 Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2014 37 

 Endometriosis - Pipeline by Camurus AB, H1 2014 38 

 Endometriosis - Pipeline by Lipicard Technologies Limited, H1 2014 39 

 Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2014 40 

 Endometriosis - Pipeline by Peptron, Inc., H1 2014 41 

 Endometriosis - Pipeline by PregLem SA, H1 2014 42 

 Endometriosis - Pipeline by EndoCeutics, Inc., H1 2014 43 

 Endometriosis - Pipeline by Isifer AB, H1 2014 44 

 Endometriosis - Pipeline by ElexoPharm GmbH, H1 2014 45 

 Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H1 2014 46 

 Endometriosis - Pipeline by AbbVie Inc., H1 2014 47 

 Endometriosis - Pipeline by Balonco GMBH, H1 2014 48 

 Endometriosis - Pipeline by Forendo Pharma Oy, H1 2014 49 

 Assessment by Monotherapy Products, H1 2014 50 

 Assessment by Combination Products, H1 2014 51 

 Number of Products by Stage and Target, H1 2014 54 

 Number of Products by Stage and Mechanism of Action, H1 2014 57 

 Number of Products by Stage and Route of Administration, H1 2014 59 

 Number of Products by Stage and Molecule Type, H1 2014 61 

 Endometriosis Therapeutics - Recent Pipeline Updates, H1 2014 109 

 Endometriosis - Dormant Projects, H1 2014 121 

 Endometriosis - Discontinued Products, H1 2014 122 

  

 List of Figures 

 Number of Products under Development for Endometriosis, H1 2014 12 

 Number of Products under Development for Endometriosis - Comparative Analysis, H1 2014 13 

 Number of Products under Development by Companies, H1 2014 14 

 Number of Products under Investigation by Universities/Institutes, H1 2014 17 

 Comparative Analysis by Late Stage Development, H1 2014 19 

 Comparative Analysis by Clinical Stage Development, H1 2014 20 

 Comparative Analysis by Early Stage Products, H1 2014 21 

 Assessment by Monotherapy Products, H1 2014 50 

 Number of Products by Top 10 Target, H1 2014 52 

 Number of Products by Stage and Top 10 Target, H1 2014 53 

 Number of Products by Top 10 Mechanism of Action, H1 2014 55 

 Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 56 

 Number of Products by Top 10 Route of Administration, H1 2014 58 

 Number of Products by Stage and Top 10 Route of Administration, H1 2014 59 

 Number of Products by Top 10 Molecule Type, H1 2014 60 

 Number of Products by Stage and Top 10 Molecule Type, H1 2014 61